LivaNova (NASDAQ:LIVN) Upgraded by StockNews.com to Strong-Buy Rating

LivaNova (NASDAQ:LIVN) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Friday.

A number of other equities research analysts also recently commented on LIVN. The Goldman Sachs Group began coverage on LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price for the company. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Stifel Nicolaus raised their target price on LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Robert W. Baird raised their target price on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Finally, Mizuho reduced their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $69.17.

LivaNova Price Performance

LivaNova stock traded down $0.35 during midday trading on Friday, reaching $51.63. The company’s stock had a trading volume of 341,476 shares, compared to its average volume of 621,525. LivaNova has a fifty-two week low of $42.75 and a fifty-two week high of $64.47. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The stock’s 50 day simple moving average is $51.37 and its 200 day simple moving average is $53.05. The firm has a market capitalization of $2.80 billion, a PE ratio of 122.93 and a beta of 1.01.

Institutional Trading of LivaNova

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LIVN. BNP Paribas Financial Markets increased its position in LivaNova by 88.6% during the 1st quarter. BNP Paribas Financial Markets now owns 42,121 shares of the company’s stock worth $2,356,000 after purchasing an additional 19,783 shares in the last quarter. Texas Permanent School Fund Corp increased its position in LivaNova by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 47,147 shares of the company’s stock worth $2,637,000 after purchasing an additional 620 shares in the last quarter. Quantbot Technologies LP purchased a new stake in LivaNova during the 1st quarter worth about $994,000. Headlands Technologies LLC increased its position in LivaNova by 287.3% during the 1st quarter. Headlands Technologies LLC now owns 6,999 shares of the company’s stock worth $392,000 after purchasing an additional 5,192 shares in the last quarter. Finally, ProShare Advisors LLC increased its position in LivaNova by 4.7% during the 1st quarter. ProShare Advisors LLC now owns 12,378 shares of the company’s stock worth $692,000 after purchasing an additional 561 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.